Targeting CXCL13 during neuroinflammation

Advances in Neuroimmune Biology

Volumn 6, Issue 1, 2015, Pages 1-8

  Huber, Amanda K ^a   Irani, David N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

CXCL13; CXCR5; Lymphoid chemokines; Multiple sclerosis; Neuroborreliosis; Post stroke dementia; Primary central nervous system lymphoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE;

CAUSAL ATTRIBUTION; DOWN REGULATION; HUMAN; IMMUNOPATHOGENESIS; IN VIVO STUDY; LIGAND BINDING; LYME DISEASE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84947261698     PISSN: 1878948X     EISSN: 18789498     Source Type: Journal    
DOI: 10.3233/NIB-150101     Document Type: Review

References (85)

1. Forster R, Matis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996; 87(6): 1037-1047.
2. Yoshie O, Imai T, Nomiyama H. Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol. 1997; 62(5): 634-644.
3. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B-cell attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998; 187(4): 655-660.
4. Mackay F, Browning JL. Turning off follicular dendritic cells. Nature 1998; 395(6697): 26-27.
5. Fu Y-X, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol. 1999; 17: 399-433.
6. Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG. Lymphotoxin-α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med. 1999; 189(2): 403-412.
7. Zlotnik A, Morales J, Hedrick JA (1999) Recent advances in chemokines and chemokine receptors. Crit Rev Immunol. 1999; 19(1): 1-47.
8. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster JD, Sedgwick JD, Browning JL, Lipp M, Cyster JG. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000; 406(6793): 309-314.
9. Moser B, Schaerli P, Laetscher P. CXCR5+ T cells: Follicular homing takes center stage in T-helper-cell responses. Trends Immunol. 2002; 23(5): 250-254.
10. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev. 2003; 195 : 117-135.
11. Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunol Rev. 2003; 195 : 58-71.
12. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N, Cyster JG. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004; 5(9): 943-952.
13. Hjelmstrom P. Lymphoid neogenesis: De novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol. 2001; 69(3): 331-339.
14. Fan L, Reilly CR, Luo Y, Dorf ME, Lo D. Cutting edge: Ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol. 2000; 164(8): 3955-3959.
15. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity. 2000; 12 : 471-481.
16. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M, Cyster JG. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002; 169(1): 424-433.
17. Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, Romani N, Lira SA. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol. 2002; 168(3): 1001-1008.
18. Mazzucchelli L, Blaser A, Kappeler A, Scharli P, Laissue JA, Baggiolini M, Uguccioni M. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest. 1999; 104(10): R49-54.
19. Winter S, Loddenkemper C, Aebischer A, Rabel K, Hoffmann K, Meyer TF, Lipp M, Hopken UE. The chemokine receptor CXCR5 is pivotal for ectopic mucosa-associated lymphoid tissue neogenesis in chronic Helicobacter pylori-induced inflammation. J Mol Med (Berl). 2010; 88(11): 1169-1180. doi:10.1007/s00109-010-0658-6
20. Nakashima Y, Isomoto H, Matshushima K, Yoshida A, Nakayama T, Nakayama M, HIsatsune J, Ichikawa T, Takeshima F, Hayashi T, Nakao K, Hirayama T, Kohno S. Enhanced expression of CXCL13 in human Helicobacter pylori-associated gastritis. Dig Dis Sci. 2011; 56(10): 2887-2894. doi:10.1007/s10620-011-1717-8
21. Yamamoto K, Nishiumi S, Yang L, Klimatcheva E, Pandina T, Takahashi S, Matsui H, Nakamura M, Zauderer M, Yoshida M. Azuma T. Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection. Mucosal Immunol. 2014; 7(5): 1244-1254. doi:10.1038/mi.2014.14
22. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004; 148(1-2): 11-23.
23. Serafini B, Rosicarelli B, Magiozzi R, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004; 14(2): 164-174.
24. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Popolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130(Pt 4): 1089-1104.
25. Aloisi F, Columba-Cabezas S, Franciotta D, Rosicarelli B, Magliozzi R, Reynolds R, Ambrosini E, Salvetti M, Serafini B. Lymphoid chemokines in chronic neuroinflammation. J Neuroimmunol. 2008; 198(1-2): 106-112. doi:10.1016/j.neuroim.2008.04.025
26. Lalor SJ, Segal BM. Lymphoid chemokines in the CNS. J Neuroimmunol. 2010; 224(1-2): 56-61. doi:10.1016/j.neuroim.2010.05.017
27. Ansel KM, Harris RB, Cyster JG. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity. 2002; 16(1): 67-76.
28. Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013; 43(5): 501-509. doi:10.1111/eci.12063. Epub 2013 Mar 20
29. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009; 6(3): 587-597. doi:10.1016/j.nurt.2009.04.013
30. Venetz D, Ponzoni M, Schiraldi M, Ferreri AJ, Bertoni F, Doglioni C, Uguccioni M. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int J Cancer. 2010; 127(10): 2300-2312. doi:10.1002/ijc.25236
31. Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphoma (PCNSL). Clin Neuropathol. 2014; 33(1): 42-49.
32. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003; 101(3): 815-821.
33. Brunn A, Montesinos-Rongen M, Strack A, Reifenberger G, Mawrin C, Schaller C, Deckert M. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol. 2007; 114(3): 271-276.
34. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M. Pathway analysis of primary central nervous system lymphoma. Blood. 2008; 111(6): 3200-3210. doi:10.1182/blood-2007-10-119099
35. Sugita Y, Terasaki M, Nakashima S, Ohshima K, Morioka M, Abe H. The perivascular microenvironment in primary central nervous system lymphomas: The role of chemokines and endothelin B receptor. Brain Tumor Pathol. 2015; 32(1): 41-48. doi:10.1007/s10014-014-0206-0
36. Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009; 15(19): 5968-5973. doi:10.1158/1078-0432.CCR-09-0108
37. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013; 121(23): 4740-4748. doi:10.1182/blood-2013-01-476333
38. Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphoma. Br J Haematol. 2014; 166(3): 311-325. doi:10.1111/bjh.12938
39. Siegal T. Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria. J Clin Neurosci. 2014; 21(5): 709-715. doi:10.1016/j.jocn.2014.02.002
40. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119(5): 1182-1189. doi:10.1182/blood-2011-10-386417
41. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaden M, Buggy JJ, Elias L. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013; 122(4): 2414-2424. doi:10.1182/blood-2013-02-482185
42. Tse KW, Lin KB, Dang-Lawson M, Guzman-Perez A, Aspnes GE, Buckbinder L, Gold MR. Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced migration, adhesion and Akt activation in follicular and marginal zone B cells. Cell Immunol. 2012; 275(1-2): 47-54. doi:10.1016/j.cellimm.2012.03.002
43. Pachner AR, Steele AC. The triad of neurologic manifestations of Lyme disease: Meningitis, cranial neuritis, and radiculoneuritis. Neurology. 1985; 35(1): 47-53.
44. Pachner AR. Borrelia bergdorferi in the nervous system: The new "great imitator." Ann NY Acad Sci. 1988; 539 : 56-64.
45. Pachner AR, Delaney E, O'Neill T, Major E. Inoculation of nonhuman primates with the N40 strain of Borrelia bergdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease. Neurology. 1995; 45(1): 165-172.
46. Pachner AR, Gelderblom H, Cadavid D. The Rhesus model of Lyme neuroborreliosis. Immunol Rev. 2001; 183: 186-204.
47. Schoenfeld R, Araneo B, Ma Y, Yang LM, Weis JJ. Demonstration of a B-lymphocyte mitogen produced by the Lyme disease pathogen, Borrelia bergdorferi. Infect Immun. 1992; 60(2): 455-464.
48. Cadavid D, O'Neill T, Schaefer H, Pachner AR. Localization of Borrelia bergdorferi in the nervous system and other organs in a nonhuman primate model of Lyme disease. Lab Invest. 2000; 80(7): 1043-1054.
49. Razavi-Encha F, Fleury-Feith J, Gherardi R, Bernuadin JF. Cytologic features of cerebrospinal fluid in Lyme disease. Acta Cytol. 1987; 31(4): 439-440.
50. Cepok S, Zhou D, Vogel F, Rosche B, Grummel V, Sommer N, Hemmer B. The immune response at onset and during recovery from Borrelia bergdorferi meningoradiculitis. Arch Neurol. 2003; 60(6): 849-855.
51. Narayan K, Dail D, Li L, Cadavid D, Amrute S, Fitzgerald-Bocarsly P, Pachner AR. The nervous system as ectopic germinal center: CXCL13 and IgG in Lyme neuroborreliosis. Ann Neurol. 2005; 57(6): 813-823.
52. Ramesh G, Borda JT, Kaushal D, Ramamoorthy R, Lackner AA, Philipp MT. Interaction of the Lyme disease spirochete Borrelia bergdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis. Am J Pathol. 2008; 173(5): 1415-1427. doi:10.2353/ajpath.2008.080483
53. Rupprecht TA, Kirschning CJ, Popp B, Kastenbauer S, Fingerle V, Pfister HW, Koedel U. Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2. Infect Immun. 2007; 75(9): 4351-4356.
54. Ramesh G, Borda JT, Gill A, Ribka EP, Morici LA, Mottram P, Martin DS, Jacobs MB, Didier PJ, Philipp MT. Possible role of glial cells in the onset and progression of Lyme neuroborreliosis. J Neuroinflammation. 2009; 6: 23. doi:10.1186/1742-2094-6-23
55. Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, Klein M, Pfister HW, Koedel U. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation. 2009; 6: 42. doi:10.1186/1742-2094-6-42
56. Senel M, Rupprecht TA, Tumani H, Pfister HW, Ludolph AC, Brettschneider J. J Neurol Neurosurg Psychiatry. 2010; 81(8): 929-933. doi:10.1136/jnnp.2009.195438
57. Tjernberg I, Henningsson AJ, Eliasson I, Forsberg P, Ernerudh J. Diagnostic performance of cerebrospinal fluid chemokine XCXL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. J Infect. 2011; 62(2): 149-158. doi:10.1016/j.jinf.2010.11.005
58. Schmidt C, Plate A, Angele B, Pfister HW, Wick M, Koedel U, Rupprecht TA. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2011; 76(12): 1051-1058. doi:10.1212/WNL.0b013e318211c39a
59. van Burgel ND, Bakels F, Kroes AC, van Dam AP. Discriminating Lyme neuroborreliosis from other neuroinflammatory disease by levels of CXCL13 in the cerebrospinal fluid. J Clin Microbiol. 2011; 49(5): 2027-2030. doi:10.1128/JCM.00084-11
60. Kowarik MC, Cepok S, Sellner J, Grummel V, Weber MS, Korn T, Berthele A, Hemmer B. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012; 9: 93. doi:10.1186/1742-2094-9-93
61. Hytonen J, Kortela E, Waris M, Puustinen J, Salo J, Oksi J. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. J Neuroinflammation. 2014; 11: 103. doi:10.1186/1742-2094-11-103
62. Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, Forsberg P, Ernerudh J. Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: Association with clinical outcome. J Infect Dis. 2004; 189(10): 1881-1891.
63. Garcia Monco JC, Wheeler CM, Benach JL, Furie RA, Lukehart SA, Stanek G, Steere AC. Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides. J Neurol Sci. 1993; 117(1-2): 206-214.
64. Kaiser R. Intrathecal immune response in patients with neuroborreliosis: Specificity of antibodies for neuronal proteins. J Neurol. 1995; 242(5): 319-325.
65. Kuenzle S, von Budingen HC, Meier M, Harrer MD, Urich E, Becher B, Goebels N. Pathogen specificity and autoimmunity are distinct features od antigen-driven immune responses in neuroborreliosis. Infect Immun. 2007; 75(8): 3842-3847.
66. BerndtsonK. Review of evidence for immune evasion and persistent infection in Lyme disease. Int J Gen Med. 2013; 6: 291-306. doi:10.2147/IJGM.S44114
67. Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, Krupp L, Gronseth G, Bever CT Jr, Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007; 69(1): 91-102.
68. Pachner AR, Amemiya K, Bartlett M, Schaefer H, Reddy K, Zhang WF. Lyme borreliosis in rhesus macaques: Effects of corticosteroids on spirochetal load and isotype switching od anti-borrelia burgdorferi antibody. Clin Diagn Lab Immunol. 2001; 8(2): 225-232.
69. Haugen M, Frederiksen JL, Degn M. B cell follicle-like structures in multiple sclerosis with a focus on the role of B cell activating factor. J Neuroimmunol. 2014; 273(1-2): 1-7. doi:10.1016/j.jneuroim.2014.05.010
70. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E. Chemokines in multiple sclerosis: CXCR12 and CXCR13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006; 129(1): 200-211.
71. Esen N, Rainey-Barger EK, Huber AK, Blakely PK, Irani DN. Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13. Glia. 2014; 62(9): 1452-1462. doi:10.1002/glia.22692
72. Esen N, Blakely PK, Rainey-Barger EK, Irani DN. Complexity of the microglial activation pathways that drive innate host responses during lethal alphavirus encephalitis in mice. ASN Neuro. 2012; 4(4): 207-221. doi:10.1042/AN201220016
73. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, Sorensen PS. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009; 73(23): 2003-2010.
74. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010; 67(6): 707-714. doi:10.1001/archneurol.2010.99
75. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, Lauda F, Kapfer T, Jesse S, Lehmensiek V, Ludolph AC, Otto M, Tumani H. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One. 2010; 5(8):e11986. doi:10.1371/journal.pone.0011986
76. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler. 2011; 17(3): 335-343.
77. Ragheb S, Li Y, Simon K, Vanhaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011; 17(7): 819-829.
78. Romme Christensen J, Ratzer R, Bornsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014; 82(17): 1499-1507. doi:10.1212/WNL.0000000000000361
79. Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: Current status. Mol Diagn Ther. 2014; 18(6): 605-617. doi:10.1007/s40291-014-0117-0
80. Columba-Cabezas S, Griguoli M, Rosicarelli B, Magliozzi R, Ria F, Serafini B, Aloisi F. Suppression of extablished experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin β receptor-Ig fusion protein. J Neuroimmunol. 2006; 179: 76-86.
81. Bagaeva LV, Rao P, Powers JM, Segal BM. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol. 2006; 176(12): 7676-7685.
82. Rainey-Barger EK, Rumble JM, Lalor SJ, Esen N, Segal BM, Irani DN. The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system. Brain Behav Immun. 2011; 25(5): 922-931. doi:10.1016/j.bbi.2010.10.002
83. Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith ES, Zauderer M. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 2015; 16: 6. doi:10.1186/s12865-015-0068-1
84. Leypoldt F, Hoftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, Rostasy K, Schlumberger W, Meyer T, Wandinger K-P, Rosenfeld MR, Graus F, Dalmau J. Investigations on CXCL13 in anti-N-Methyl-D-Aspartate receptor encephalitis. JAMA Neurol. 2015; 72(2): 180-186. doi:10.1001/jamaneurol.2014.2956
85. Doyle KP, Quach LN, Sole M, Axtell RC, Nguyen TV, Soler-Llavina GJ, Jurado S, Han J, Steinman L, Longo FM, Schneider JA, Malenka RC, Buckwalter MS. B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci. 2015; 35(5): 2133-2145. doi:10.1523/JNEUROSCI.4098-14.2015